These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22890768

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
    Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M.
    Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
    Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ.
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
    Clifton IJ, Whitaker P, Metcalfe R, Phillip M, Shaw N, Conway SP, Peckham DG.
    J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
    Brüggemann RJ, Antonius T, Heijst Av, Hoogerbrugge PM, Burger DM, Warris A.
    Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of voriconazole in children.
    Chen J, Chan C, Colantonio D, Seto W.
    Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
    Meletiadis J, Al-Saigh R, Velegraki A, Walsh TJ, Roilides E, Zerva L.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.
    Tell LA, Clemons KV, Kline Y, Woods L, Kass PH, Martinez M, Stevens DA.
    Med Mycol; 2010 Mar; 48(2):234-44. PubMed ID: 19548171
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
    Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW.
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
    Seyedmousavi S, Brüggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW.
    J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T.
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
    Seyedmousavi S, Brüggemann RJ, Melchers WJ, Verweij PE, Mouton JW.
    Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
    [Abstract] [Full Text] [Related]

  • 19. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
    Al-Saigh R, Elefanti A, Velegraki A, Zerva L, Meletiadis J.
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
    [Abstract] [Full Text] [Related]

  • 20. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
    Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.